Literature DB >> 12114423

DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia.

Guillermo Garcia-Manero1, Jerry Daniel, Terry L Smith, Steven M Kornblau, Ming-Sheng Lee, Hagop M Kantarjian, Jean-Pierre J Issa.   

Abstract

PURPOSE: Aberrant methylation of promoter-associated CpG islands is an epigenetic oncogenic mechanism. The objective of this study was to define the methylation characteristics of patients with acute lymphocytic leukemia (ALL). EXPERIMENTAL
DESIGN: Using bisulfite-PCR followed by restriction enzyme digestion (COBRA), we have analyzed the methylation status of 10 promoter-associated CpG islands in 80 untreated adult patients with ALL.
RESULTS: Mean methylation density of MDR1, THBS2, MYF3, ER, p15, THBS1, CD10, C-ABL, and p16 was 24.5%, 20.8%, 17.6%, 16.1%, 11.3%, 8.9%, 4.5%, 3.7%, and 1.3% respectively. p73 was methylated in 17 of 80 cases (21.2%). A total of 86.2% of the cases had methylation of at least one gene, and 42.5% of the cases had methylation of three or more genes. MDR1 methylation was inversely correlated with age (P = 0.01). CD10 methylation inversely correlated with CD10 expression (P = 0.0001). Methylation of MDR1 and THBS1 was inversely associated with the presence of the Philadelphia chromosome, whereas C-ABL methylation correlated with the presence of the p210 variant of the Philadelphia chromosome. In univariate analysis, methylation of THBS1 was associated with a favorable outcome (P = 0.02), whereas methylation of p73, p15, and C-ABL was associated with a trend toward worse prognosis.
CONCLUSIONS: Aberrant DNA methylation of promoter-associated CpG islands is very common in adult ALL and potentially defines subgroups with distinct clinical and biological characteristics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12114423

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  44 in total

1.  Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.

Authors:  Wei-Gang Tong; William G Wierda; E Lin; Shao-Qing Kuang; B Nebiyou Bekele; Zeev Estrov; Yue Wei; Hui Yang; Michael J Keating; Guillermo Garcia-Manero
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

Review 2.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 3.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

4.  FHIT promoter DNA methylation and expression analysis in childhood acute lymphoblastic leukemia.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Simin Sadeghi-Bojd; Mohsen Taheri
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

5.  The association between non-Hodgkin lymphoma and methylation of p73.

Authors:  Jing-Hong Pei; Sai-Qun Luo; Yan Zhong; Jiang-Hua Chen; Hua-Wu Xiao; Wei-Xin Hu
Journal:  Tumour Biol       Date:  2011-08-03

6.  Analysis of molecular alterations in laterally spreading tumors of the colorectum.

Authors:  Tamotsu Sugai; Wataru Habano; Ryo Takagi; Hiroo Yamano; Makoto Eizuka; Noriyuki Arakawa; Yayoi Takahashi; Eiichiro Yamamoto; Keisuke Kawasaki; Syunichi Yanai; Kazuyuki Ishida; Hiromu Suzuki; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2016-10-04       Impact factor: 7.527

Review 7.  Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies.

Authors:  Oliver Galm; Manel Esteller
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

8.  DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.

Authors:  W S Stevenson; O G Best; A Przybylla; Q Chen; N Singh; M Koleth; S Pierce; T Kennedy; W Tong; S-Q Kuang; G Garcia-Manero
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

Review 9.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

10.  The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

Authors:  Anna Scuto; Mark Kirschbaum; Claudia Kowolik; Leo Kretzner; Agnes Juhasz; Peter Atadja; Vinod Pullarkat; Ravi Bhatia; Stephen Forman; Yun Yen; Richard Jove
Journal:  Blood       Date:  2008-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.